Adusumilli et al. (2019) in a phase 1 trial used mesothelin-specific CAR-T cells in combination with anti-PD 1 checkpoint inhibitors for the treatment of primary (malignant mesothelioma) and secondary (metastatic breast and lung carcinoma) malignant pleural neoplasms. The gene discussed is RPL17; the disease is pleural cancer.